Swiss Medica Inc. Neuanfang/Turnaround 2007 - 500 Beiträge pro Seite

[RLD]

Ich starte ein neuen Thread, rund um die Swiss Medica Inc. aus Kanada.

Wie SWME im August bekannt gab, ging im Zusammenhang mit dem Einstieg in den USA Markt eine Menge schief. Nun soll laut eigenen Aussagen ein Neuanfang geschaffen werden und an den alten Erfolgen angeknüpft werden.

[RLD]

Antwort auf Beitrag Nr.: 32.172.357 von RLD am 27.10.07 13:16:20

Swiss Medica to Launch New USA Distribution Channel

TORONTO, Aug. 8 /PRNewswire-FirstCall/ -- Swiss Medica (OTC Bulletin Board: SWME) announced today that it will launch a new distribution strategy in the USA focused on direct-to-consumer selling and distribution via medical professionals. In addition, Swiss Medica has decided to strategically exit the working capital intensive USA national pharmacy channel that caused the bulk of Swiss Medica's recent operational and financial difficulties.

Swiss Medica launched O24 Pain Neutralizer and O24 Fibromyalgia in 2005 in national pharmacy chains in the USA, after a similar successful launch in Canada. Swiss Medica made a large investment in upfront inventory for the retailers in advance of the launch, spent several millions dollars on radio and other mainstream marketing in the USA and carried receivables from pharmacies for six months plus in most cases. Swiss Medica's unsuccessful experience with USA retailers were due to:

1) Mainstream short-form radio marketing that could not differentiate O24's superior efficacy and science from its competitors.

2) An overinvestment in inventory for re-orders that did not materialize

3) Predatory supplier practices of large pharmacies who charged large fees without approval, returned inventory that was damaged for full credit and had extremely slow payment processes for small manufacturers. Swiss Medica continues to pursue collections from its USA national pharmacy customers.

Swiss Medica recognized that the national pharmacy retail channel is not the most appropriate channel in the United States for O24 whose unique patent and clinical/medical trials need to be explained in detail in formats such as the 1 hour branded radio shows that were successful in Canada, but are not as available in the United States. In addition O24's efficacy can be best proven by using a towelette sample of O24.

The USA direct-to-consumer marketplace is the most developed and elaborate in the world, allowing manufacturers many means to bypass retailers and access consumers directly. Swiss Medica is working to launch the distribution of O24 with a major USA-based direct-to-consumer marketing organization which focuses on marketing products through mailing samples of products to the millions of customers in their database and then auto-shipping regular orders of products to customers who opt-into the re-order program. This company chose O24 after an extensive product due diligence process and has estimated that it can build a large regular direct order business for a private label O24 due to the extremely high efficacy and customer satisfaction after the use of a single compact O24 towelette. Another pain relief product distributed by the same company experienced initial demand that translated in several million dollars of annualized wholesale revenues to the manufacturer.

The direct-to-consumer channel is much more attractive to Swiss Medica due to lower investments in upfront inventory, better payment terms from direct- to-consumer marketing partners and no need to spend consumer marketing dollars in the United States.

[RLD]

Swiss Medica Announces Corporate Update

TORONTO, June 20 /PRNewswire-FirstCall/ -- Swiss Medica, Inc. (OTC Bulletin Board: SWME) announced today that

1) Swiss Medica recently filed its 10KSB for the year ended December 31, 2006 and its 10QSB for the 3 months ended March 31, 2007 with the Securities & Exchange Commission. The filings are accessible in the investor relation's section of www.swissmedica.com.

2) As Swiss Medica Inc. has now filed the outstanding 10KSB and 10QSB, it is current with its filings and its symbol has now been changed back to SWME.OB.

3) Swiss Medica has been undertaking a large restructuring of its operations and management, which has included staff reductions, cost cutting and a refocusing of its distribution strategy. Details of this operational restructuring are included in recent S.E.C. filings. In addition, Swiss Medica will be issuing further press releases outlining its strategic repositioning as well as management restructuring.

4) Swiss Medica has also undertaken a restructuring of its balance sheet with a focus on debt restructuring and debt reduction. Details of these debt restructurings have been included in recent S.E.C. filings with further restructuring transaction details to be included in press releases and S.E.C. filings in the weeks to come.

5) Swiss Medica has been raising capital to undertake the restructuring, reduce its debt and implement its strategic repositioning program. Details of these financing activities will be included in S.E.C. filings including the 8K filed with the S.E.C. on May 29, 2007.

Swiss Medica will make further announcements with respect to details of its restructuring plans.

[RLD]

Swiss Medica Launches New Multi-Channel Distribution Strategy for Canada

TORONTO, July 12 /PRNewswire-FirstCall/ -- Swiss Medica, Inc. (OTC Bulletin Board: SWME) announced today it has launched a new multi-channel distribution strategy for its Canadian business segment focused on the retail, professional and private label channels.

Swiss Medica launched O24 Pain Neutralizer in Canadian national retailers in the fall of 2004 with an aggressive public relations and marketing strategy focused on 30 minute informational radio segments, in-store sampling of O24, consumer trade shows and detailing of medical professionals. O24 was well received by the Canadian marketplace and Swiss Medica's Canadian market revenues in 2005 were approximately US$1.6 million. O24 Pain Neutralizer's 1 ounce bottle was the third best selling SKU in Canada in 2005 in retailers and outsold many major brands including Ben-Gay(TM), Tiger Balm(TM) and Icy Hot(TM).

In 2006, Swiss Medica launched O24 Fibromyalgia into the Canadian retail marketplace and lowered its Canadian marketing spend to focus on its USA retail launch. In addition, it focused its lower Canadian media spend on mainstream marketing strategies including short-form radio ads and sponsorships. The combination of lower marketing dollars and ineffective mainstream media resulted in reduced O24 sales in Canada of approximately US$700,000.

Despite the reduction in sales, O24 has gained a loyal following in Canada with both consumers and the physician community who are looking for a safe and effective alternative for pain, versus both prescription and over-the-counter pills. In addition, O24 is available in most major retailers in Canada and has secured attractive shelf placement in most retailers. Swiss Medica plans to re-launch its aggressive guerilla marketing strategies (from 2005) in the fall of 2007 with long-form 30 minute radio segments with doctors on the radio talking about O24 and call in questions from the audience. In addition, O24 will be re-introduced to the physician community and an aggressive in-store sampling campaign for O24 will recommence to allow consumers to quickly recognize the superior efficacy of O24 versus other products. Swiss Medica believes that it can grow its monthly Canadian retail revenues to levels higher than 2005 within 12 months.

In addition, Swiss Medica has commenced private labelling O24 to Canadian distributors of healthcare products who are selling Swiss Medica's patented product using their own brands. Swiss Medica has completed two private label distribution deals thus far in the past year. Swiss Medica supports its private label customers with training and previously developed marketing and product science literature, but the private label customer must spend its own marketing and media dollars to support their private label brands. These and other private label deals have the potential to materially grow Swiss Medica's Canadian revenues in 2008 and provide excellent net margins as Swiss Medica is not spending dollars on consumer media to support these private label brands.

Swiss Medica is currently in discussions with several large medical product distributors who have expressed strong interest in distributing O24 to hospitals, clinics and healthcare professionals. O24's unique patented process, its strong medical and clinical trial results and its safety profile make it an ideal candidate for the Canadian healthcare professional market. Swiss Medica expects to conclude a distribution arrangement for the professional marketplace by the end of 2007.

Ben Gay is a registered trademark of Johnson & Johnson. Tiger Balm is a registered trademark of Haw Par Healthcare Ltd. Icy Hot is a trademark of Chattem, Inc.

[RLD]

= > die SWME Inc. sucht also den Neuanfang in diesem Herbst/Winter.
Der kurs hat sich fast unberücksicht davon entwickelt.


Aktienanzahl: 168 Mio.
Kurs: 0.009 USD
Marktkap.: 1.5 Mio. USD

Umsatz Kanada 2005: 1.6 Mio. USD
Umsatz Kanada 2006: 700 TUSD
Umsatz Kanada 2008: ca. 1.6 Mio. + X USD (SWME -Prognose)
Umsatz USA 2008: (keine Angaben)

[jcb123]

04.08.2008 - Comeback
Lange war es ruhig um die swissmedica Inc. , aber das könnte sich bald ändern.

Anleger rechneten schon mit der Insolvenz des 2005 umjubelten Biotech-Unternehmen. Die Umsätze kletterten 2004 und 2005 von Quartal zu Quartal prozentual im zwei bis dreistelligen Bereich. Von anfänglichen Ausstellungen auf kleinen regionalen Messen, schafften es die Produkte bis ins landesweite Fernsehen. Nachrichtensender berichteten über die tolle Wirksamkeit der neuen Naturheilmittel. Selbst ein eigener Werbespot wurde gedreht und ausgestrahlt. Große US-Handelsketten wie RiteAid und CVS nahmen die Produkte in ihr Sortiment.

Doch dann brach der Umsatz ein. Nach eigenen Unternehmensangaben führten falsche Absprachen mit den Handelsketten zu der Rückgabe von mehreren tausenden Produkten. Als Newcomer hatte das Unternehmen zudem kaum Cash-Reserven und sich mit hohen Marketingkosten bereits übernommen. Der große amerikanische Markt brach dem Unternehmen sprichwörtlich "das Genick".

Anfang 2007 dann ein erster Hoffnungsschimmer. Das Unternehmen erhielt eine Finanzspritze von knapp 600 TUSD. Kurz darauf wurde ein Unternehmens-Update veröffentlicht. In diesem ging hervor, dass sich während der Funkstille viel getan haben soll. Die Geschäftsstrategie wurde überarbeitet und interne Arbeitsabläufe gestrafft.

Mitte Juli wurde dann das Comeback angekündigt. Ab Hebst will das Unternehmen in Kanada erneut eine Werbeoffensive starten. Der kanadische Markt ist im Gegensatz zum amerikanischen Markt wesentlich überschaubarer und loyaler. Der amerikanische Markt erfordert schon aufgrund der Größe ein hohes Werbebudget. Zudem zählen die amerikanischen Kunden zu "unloyalen-Kunden", soll heißen, sie lassen sich leicht von anderen Werbekampagnen beeinflussen und sind einem einzelnen Produkt nur selten treu.

Die swissmedica Inc. wird sich daher auf den kanadischen Markt konzentrieren und zusätzlich Lizenzen an andere Unternehmen vergeben. Das führt zu zusätzliche Lizenz-Einnahmen, ohne hohe Werbeausgaben aufbringen zu müssen und verbessert zudem die Geschäftsstruktur.

Wir halten daher nach wie vor am Unternehmen und deren Produkten fest. Das Management hat bewiesen, auch in schwierigen Zeiten eine Lösung zu finden. Nun liegt es an der Umestzung.

Quelle: www.dellarue.de